Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis

• by Andreas Karlsson Rosenblad, Bassam Mazin Hashim, Per Lindblad, Börje Ljungberg

• August 7, 2024

Marc Machaalani, MD on MAdCAM-1

Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.

• November 5, 2025

• 1 min

Fox Chase Cancer Center and Temple Researchers Highlight Need for Molecular Testing in Diagnosing Two Types of Kidney Cancer

Genetic testing may be the most effective way for researchers to distinguish between a rare form of kidney cancer and another that is more common, potentially preventing misdiagnoses, according to a recent study by researchers at Fox Chase Cancer Center and Temple University Hospital.

• by

• October 8, 2025

• 3 min

DNER drives glycolytic reprogramming in renal cell carcinoma by activating the JAK2/STAT3 signaling pathway

• by Anrui Li, Jing-wen Xu, Jian-hua Qin, Qi Yuan, Lichen Teng

• May 22, 2026